Designing Longevity
Skip to main content
Emerging ResearchPeptide

Humanin

The rescue factor

Mitochondrial-Derived Peptide

Last updated: August 2026
Share:

Evidence Level: Emerging Research

Very new, early-stage research, high uncertainty

Regulatory Status: Not approved anywhere and not in reported clinical development. Sold as a "research chemical."

Humanin is a 24-amino-acid peptide encoded inside your DNA, discovered in 2001 in a rare surviving neuron from an Alzheimer's patient's brain. It protects cells from a wide range of lethal stresses in the lab, and higher blood levels track with longevity in humans. No clinical trial has ever administered it to a person.

How It Works

Humanin has one of the best discovery stories in modern biology, and understanding it explains both why the peptide is interesting and where the evidence stops.

How it was found. Researchers were studying the occipital lobe of a patient who died with Alzheimer's disease, a region where, unusually, some neurons had survived. Rather than asking why the other neurons died, they asked what the survivors were making that the dead ones were not. The answer was a short peptide encoded inside the 16S ribosomal RNA gene. They named it humanin, and the 2001 paper called it "a rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes."

What it does. Humanin is broadly cytoprotective. In laboratory conditions it protects cells from amyloid-beta toxicity, oxidative stress, serum deprivation, and other lethal insults. It works partly by blocking BAX, a protein that punches holes in membranes to initiate cell death, and partly through a cell-surface receptor complex that activates survival signaling. It also improves insulin sensitivity in animal models.

Together with MOTS-c, humanin established that are not just power plants but endocrine organs, sending peptide signals about cellular stress to the rest of the body.

The human longevity data is real, and it is correlational. Circulating humanin levels decline substantially with age. Higher levels have been associated with longevity, and the offspring of centenarians have been reported to carry higher humanin levels than controls. A humanin variant called P3S has been associated with longevity in APOE4 carriers and with resistance to APOE4-related brain pathology.

That is genuinely interesting human data. It is also, entirely, observational. Higher humanin might protect you, or living longer and staying metabolically healthy might produce higher humanin, or both might follow from something else. Correlational biomarker data cannot distinguish these, and the history of longevity biomarkers is full of associations that turned out to be consequences rather than causes.

What has never happened. No clinical trial has administered humanin, or the more potent analog HNG, to a human being. There is no human safety data, no human pharmacokinetic data, and no efficacy data. Everything sold as humanin is being taken on the strength of mouse studies and correlational human observations.

Evidence by Outcome

Each claim below is rated using a GRADE-aligned five-tier system. Same molecule, different outcomes, different evidence.

Evidence at a glance

How we grade

Want to see how this compares to every other peptide? Browse the full evidence matrix, where every graded claim is grouped by outcome and sorted by certainty.

Longevity biomarkersLow certainty

Higher circulating humanin levels are associated with longevity in humans.

Population: Human cohorts including centenarian offspring and APOE4 carriers

Why this rating

This is a real, replicated human observation supported by both circulating-level studies and genetic variant analysis, which is stronger than most longevity biomarker claims. It remains low certainty because it is entirely observational. Higher humanin may protect, or it may simply reflect better underlying metabolic health and more physical activity, both of which raise humanin and independently extend life. No intervention study can currently separate these.

GRADE downgrade factors applied

  • Risk of bias: Methodological flaws in the studies (e.g. lack of blinding, allocation concealment, high attrition).
  • Indirectness: Studied population, intervention, comparator, or outcome differs from the question being answered.

Supporting studies

Reviewed 2026-08-24· Designing Longevity EditorialHow we grade
Cognitive functionPreclinical certainty

Administering humanin protects neurons or prevents cognitive decline.

Population: No human population has been studied. Evidence is from cell culture and animal models.

Why this rating

The neuroprotective effect in laboratory conditions is well documented and was the basis of the original discovery. No clinical trial has ever administered humanin or its analog HNG to a human being, so there is no human safety, pharmacokinetic, or efficacy data. Whether an injected peptide even reaches the brain in meaningful concentration is unanswered. Alzheimer's is also a field where an unusually large number of compounds that protected neurons in a dish did nothing in people.

Supporting studies

Reviewed 2026-08-24· Designing Longevity EditorialHow we grade

Potential Benefits

  • A genuine discovery with a well-documented mechanism, published in high-quality journals since 2001
  • Broadly cytoprotective in laboratory conditions across many different lethal stresses
  • Blocks BAX-mediated cell death and activates survival signaling through a defined receptor complex
  • Improved insulin sensitivity and metabolic markers in animal models
  • Human observational data links higher levels to longevity, including in centenarian offspring
  • A humanin genetic variant has been associated with resistance to APOE4-related brain pathology

Risks & Considerations

  • No clinical trial has ever administered humanin to a human, so there is no safety or efficacy data
  • The human longevity link is correlational, and correlation with longevity is a notoriously unreliable guide to what works
  • No published human pharmacokinetic data, including whether an injected peptide reaches the brain at all
  • Broad cell-survival promotion is not automatically desirable, since keeping damaged cells alive is one way cancer starts
  • Very short half-life, which is why the analog HNG exists, and HNG has no human data either
  • Unregulated supply with no verified identity or purity
  • Marketed for Alzheimer's prevention, a claim with no human evidence whatsoever

Dosing Information

There is no human dose. No human study has been conducted. Any protocol you find online is invented.

  • •Animal studies have used a range of doses and routes, including intracerebroventricular administration, which is not a route available outside a laboratory
  • •HNG, a variant with glycine substituted at position 14, is substantially more potent in animal models and is what most vendors actually sell
  • •Community protocols suggesting a few milligrams subcutaneously have no published basis of any kind
  • •Native humanin has a very short half-life, so subcutaneous dosing may not achieve meaningful exposure
  • •We are not publishing a protocol for a compound never administered to a human under study conditions

Need to mix this from a vial?

Use our reconstitution calculator to get the exact insulin syringe units to draw.

Practical Tips

  • 1Read the humanin literature as biology rather than as a product. The discovery is excellent and the translation has not started
  • 2Correlational longevity biomarkers are among the easiest findings to misread. Higher humanin in centenarian offspring may be a result of their health, not a cause
  • 3If you are interested in the -derived peptide family, MOTS-c at least has human exercise data
  • 4The things that reliably raise humanin in animal studies include exercise and caloric restriction, both of which you can do today
  • 5Be especially skeptical of Alzheimer's prevention marketing here. The discovery context makes that pitch easy and the evidence for it does not exist

Key Research

A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta

Proceedings of the National Academy of Sciences, 2001

The discovery paper. Humanin was identified from surviving neurons in an Alzheimer's brain and shown to protect cells from death caused by a wide range of familial Alzheimer's disease genes and amyloid-beta.

View Study

Detailed characterization of neuroprotection by a rescue factor humanin against various Alzheimer's disease-relevant insults

Journal of Neuroscience, 2001

Characterized the range of Alzheimer's-relevant insults humanin protects neurons against in laboratory conditions.

View Study

The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan

Aging, 2020

Linked humanin levels to lifespan and healthspan across species, and reported that circulating humanin declines with age in humans.

View Study

Humanin variant P3S is associated with longevity in APOE4 carriers and resists APOE4-induced brain pathology

Aging Cell, 2024

A humanin genetic variant was associated with longevity in carriers of the APOE4 Alzheimer's risk gene and with resistance to APOE4-related brain pathology.

View Study

Want to learn more?

Explore related content and talk to a healthcare provider.

Browse All TreatmentsFind Your Goal

Always consult a healthcare provider before starting any treatment.This treatment has very early human evidence.

Frequently Asked Questions

What is humanin?

Humanin is a 24-amino-acid peptide encoded inside your DNA, in the 16S ribosomal RNA gene. It was discovered in 2001 in surviving neurons taken from the brain of an Alzheimer's patient. Researchers asked what those rare survivors were producing that the dead neurons were not, and humanin was the answer. It protects cells from a wide range of lethal stresses.

Are there human trials of humanin?

No. No clinical trial has ever administered humanin, or its more potent analog HNG, to a human being. There is no human safety data, no pharmacokinetic data, and no efficacy data. The human evidence that does exist is observational: measurements of naturally circulating humanin levels and their association with age and longevity.

Does humanin actually extend lifespan?

In humans, nobody knows. Higher circulating humanin levels are associated with longevity, and centenarian offspring have been reported to carry higher levels. That is a real and replicated observation. It is also correlational, and the direction of causation is unresolved: exercise and good metabolic health both raise humanin and independently extend life, so humanin may be a marker of health rather than a cause of it.

Can humanin prevent Alzheimer's disease?

There is no human evidence for this. Humanin protects neurons from amyloid-beta and other Alzheimer's-relevant insults in laboratory conditions, which is how it was discovered, and a humanin genetic variant has been associated with resistance to APOE4-related brain pathology. None of that is the same as a trial. Alzheimer's research is particularly full of compounds that protected neurons in a dish and failed completely in people.

What is HNG and how is it different from humanin?

HNG is a modified humanin with glycine substituted at position 14, which makes it substantially more potent in animal models. Native humanin has a very short half-life, so most research and most commercial product uses HNG or a similar analog. Neither has been given to a human in a study, so the increased potency is a laboratory observation rather than a clinical advantage.

How is humanin different from MOTS-c?

Both are -derived peptides, encoded in mitochondrial DNA and released as signals to the rest of the body. Humanin is primarily cytoprotective and neuroprotective, blocking cell death pathways. MOTS-c is metabolic, activating in muscle and fat. MOTS-c has the advantage of documented human data showing it is released during exercise; humanin has the advantage of a longer research history and human longevity association data.

How can I raise my humanin levels naturally?

The interventions shown to raise -derived peptides in research are exercise and caloric restriction. Both are free, both have extensive human outcome data, and both raise humanin as one of many downstream effects. That is a considerably better-supported approach than injecting a peptide that has never been given to a human under study conditions.

New to Peptides?

Learn the basics of peptide therapy, how to inject safely, and what to look for in quality sources.

What Are Peptides? Peptide Safety Guide

Related Goals

The Slow Aging GuideThe Sharper Mind Guide

Related Peptides

MOTS-cMitochondrial-Derived Peptide
SS-31 (Elamipretide)Mitochondria-Targeting Tetrapeptide
EpithalonPineal Tetrapeptide

Disclaimer: This information is for educational purposes only and is not medical advice. Many peptides discussed are not FDA-approved for human use. Always consult with a qualified healthcare provider before starting any treatment. Evidence levels and regulatory status can change, this content was last updated August 2026.

Found this helpful? Share it or save it for later.

Share: